Literature DB >> 16197495

Social and medical impact, sleep quality and the pharmaceutical costs of heartburn in Taiwan.

C-L Lu1, H-C Lang, F-Y Chang, T-J Chen, C-Y Chen, J-C Luo, S-D Lee.   

Abstract

BACKGROUND: Little is known about the social and medical burdens of heartburn in Asia. AIM: To assess the impact of heartburn in Taiwan.
METHODS: We applied a questionnaire to 2018 apparently healthy adult Chinese receiving a routine health maintenance programme. Costs of heartburn-related prescriptions were obtained from the Bureau of National Health Insurance of Taiwan.
RESULTS: Heartburn prevalence (>1 episode/week) was 7%. Smoking and increased body mass index were associated with heartburn occurrence. Heartburn sufferers reported more atypical gastro-oesophageal reflux disease symptoms, e.g. chest pain, dysphagia and globus. They were more likely to consult physicians, and have an increased frequency and number of days of absenteeism, irrespective of upper gastrointestinal or nongastrointestinal-related illnesses. They experienced sleep disturbances more frequently. The 62 heartburn consulters (48%) were more likely to have co-existing globus, visited physicians more, had more absenteeism, suffered from more sleep disturbances and had higher costs for antacids, proton pump inhibitors, hypnotic/sedatives, tranquilizers and antidepressants than nonconsulters.
CONCLUSIONS: Heartburn prevalence in Taiwan is lower than in Western countries. Nevertheless, heartburn in Taiwanese creates a significant burden in terms of social impact, health resource utilization, sleep quality and pharmaceutical costs. The increased costs of psychoactive drugs in consulters suggest that anxiety/depression affects their health-seeking behaviour.

Entities:  

Mesh:

Year:  2005        PMID: 16197495     DOI: 10.1111/j.1365-2036.2005.02664.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  8 in total

1.  Development of a frequent heartburn index.

Authors:  Donald E Stull; Patricia van Hanswijck de Jonge; Katherine Houghton; Christopher Kocun; David W Sandor
Journal:  Qual Life Res       Date:  2011-01-12       Impact factor: 4.147

2.  Irritable bowel syndrome and negative appendectomy: a prospective multivariable investigation.

Authors:  Ching-Liang Lu; Chun-Chu Liu; Jong-Ling Fuh; Pei-Yi Liu; Chew-Wun Wu; Full-Young Chang; Shou-Dong Lee
Journal:  Gut       Date:  2007-05       Impact factor: 23.059

3.  Gastroesophageal reflux disease and risk for bipolar disorder: a nationwide population-based study.

Authors:  Wan-Shan Lin; Li-Yu Hu; Chia-Jen Liu; Chih-Chao Hsu; Cheng-Che Shen; Yen-Po Wang; Yu-Wen Hu; Chia-Fen Tsai; Chiu-Mei Yeh; Pan-Ming Chen; Tung-Ping Su; Tzeng-Ji Chen; Ti Lu
Journal:  PLoS One       Date:  2014-09-25       Impact factor: 3.240

4.  5-alpha-reductase inhibitor therapy postpones urine retention and prostate surgery in patients with prostate enlargement and a maximum uroflow rate of less than 15 ml/sec.

Authors:  Wenhsu Lin; Shangsen Lee; Jengyuan Wu; Yuhung Kuo; Tengfu Hsieh
Journal:  PLoS One       Date:  2017-04-10       Impact factor: 3.240

5.  Association between different anticholinergic drugs and subsequent dementia risk in patients with diabetes mellitus.

Authors:  Yu-Wan Yang; Hsin-Ho Liu; Tien-Huang Lin; Hsun-Yang Chuang; Tengfu Hsieh
Journal:  PLoS One       Date:  2017-04-06       Impact factor: 3.240

6.  Silent gastroesophageal reflux disease.

Authors:  Ching-Liang Lu
Journal:  J Neurogastroenterol Motil       Date:  2012-07-10       Impact factor: 4.924

7.  Maximum Urine Flow Rate of Less than 15ml/Sec Increasing Risk of Urine Retention and Prostate Surgery among Patients with Alpha-1 Blockers: A 10-Year Follow Up Study.

Authors:  Hsin-Ho Liu; Tsung-Hsun Tsai; Shang-Sen Lee; Yu-Hung Kuo; Tengfu Hsieh
Journal:  PLoS One       Date:  2016-08-11       Impact factor: 3.240

8.  Metformin Use Correlates with Reduced Risk of Gallstones in Diabetic Patients: A 12-Year Follow-up Study.

Authors:  Kuan-Fu Liao; Hsun-Yang Chuang; Shih-Wei Lai
Journal:  Front Pharmacol       Date:  2017-10-24       Impact factor: 5.810

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.